Trials / Terminated
TerminatedNCT06061081
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living With HIV-1
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VH3739937 | VH3739937 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-12-21
- Primary completion
- 2024-08-27
- Completion
- 2024-08-27
- First posted
- 2023-09-29
- Last updated
- 2025-10-20
- Results posted
- 2025-10-20
Locations
18 sites across 6 countries: United States, Argentina, Greece, Italy, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06061081. Inclusion in this directory is not an endorsement.